Literature DB >> 15046254

HIV's evasion of host's NK cell response and novel ways of its countering and boosting anti-HIV immunity.

Ali Ahmad1, Rasheed Ahmad.   

Abstract

NK cells were characterized by their ability to spontaneously kill certain tumor and virus-infected cells. They constitute first line of defense against invading pathogens and usually become activated in viral infections particularly in early phases. Activated NK cells play a crucial role in the induction and amplification of virus-specific immunity by providing IFN-gamma and "danger signal". The functional activities of NK cells are regulated by a balance between the engagement of their inhibitory and activating receptors. In recent years, the discovery of several MHC and non-MHC binding NK receptors has provided important insights regarding NK cell biology and its role in viral infections. These receptors are increasingly being viewed as important regulators of immune response. Like many other viruses, HIV also seems to activate NK cells. However, several studies have reported compromised NK cell functions in HIV-infected individuals. The virus employs several strategies to counter the host's NK cell response, e.g., a differential downregulation of MHC class I molecules on the surface of infected cells, a dysregulated production of NK cell function-enhancing cytokines, direct inhibitory effects of certain viral proteins on NK cell functions, and changes in the expression of NK cell receptors, etc. The individuals expressing activating NK cell receptors and their cognate MHC ligands have activated NK cells. The development of AIDS is significantly delayed in these individuals after HIV infection. The discovery of NK receptors and their ligands has opened new avenues of developing AIDS vaccine and boosting innate and adaptive antiviral immunity in HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15046254     DOI: 10.2174/1570162033485267

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  6 in total

Review 1.  Advances in FIV vaccine technology.

Authors:  Elizabeth W Uhl; Marcus Martin; James K Coleman; Janet K Yamamoto
Journal:  Vet Immunol Immunopathol       Date:  2008-01-20       Impact factor: 2.046

2.  Alterations of natural killer cell and T-lymphocyte counts in adults infected with human immunodeficiency virus through blood and plasma sold in the past in China and in whom infection has progressed slowly over a long period.

Authors:  Yongjun Jiang; Hong Shang; Zining Zhang; Yingying Diao; Di Dai; Wenqing Geng; Min Zhang; Xiaoxu Han; Yanan Wang; Jing Liu
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

Review 3.  Antibody vs. HIV in a clash of evolutionary titans.

Authors:  Dennis R Burton; Robyn L Stanfield; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-11       Impact factor: 11.205

4.  Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals.

Authors:  Domenico Mavilio; Gabriella Lombardo; Janet Benjamin; Diana Kim; Dean Follman; Emanuela Marcenaro; M Angeline O'Shea; Audrey Kinter; Colin Kovacs; Alessandro Moretta; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

5.  Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects.

Authors:  Ivan Stratov; Amy Chung; Stephen J Kent
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

Review 6.  Innate immune evasion strategies by human immunodeficiency virus type 1.

Authors:  Debjani Guha; Velpandi Ayyavoo
Journal:  ISRN AIDS       Date:  2013-08-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.